Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

by Reham Abdel-Wahab, Gauri R. Varadhachary, Priya R. Bhosale, Xuemei Wang, David R. Fogelman, Rachna T. Shroff, Michael J. Overman, Robert A. Wolff, Milind Javle
Published 2018-05-01

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma

by Jane E. Rogers, Jonathan D. Mizrahi, Lianchun Xiao, Chirayu Mohindroo, Rachna T. Shroff, Robert Wolff, Gauri R. Varadhachary, Milind M. Javle, Michael Overman, David R. Fogelman, Kanwal P. S. Raghav, Shubham Pant, Florencia McAllister
Published 2020-08-01

Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials

by Timothy A. Lin, Clifton David Fuller, Vivek Verma, Walker Mainwaring, Andres F. Espinoza, Austin B. Miller, Amit Jethanandani, Dario Pasalic, Prajnan Das, Bruce D. Minsky, Charles R. Thomas, David R. Fogelman, Vivek Subbiah, Ishwaria M. Subbiah, Ethan B. Ludmir
Published 2020-09-01

Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer.

by Amir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, Ganiraju Manyam, Bryan K Kee, David R Fogelman, Arvind Dasari, Kanwal Raghav, Eduardo Vilar, Shanequa Manuel, Imad Shureiqi, Robert A Wolff, Keyur P Patel, Raja Luthra, Kenna Shaw, Cathy Eng, Dipen M Maru, Mark J Routbort, Funda Meric-Bernstam, Scott Kopetz
Published 2017-01-01

Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients

by Chirayu Mohindroo, Merve Hasanov, Jane E. Rogers, Wenli Dong, Laura R. Prakash, Seyda Baydogan, Jonathan D. Mizrahi, Michael J. Overman, Gauri R. Varadhachary, Robert A. Wolff, Milind M. Javle, David R. Fogelman, Michael T. Lotze, Michael P. Kim, Matthew H.G. Katz, Shubham Pant, Ching‐Wei D. Tzeng, Florencia McAllister
Published 2021-08-01